These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20661272)

  • 1. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.
    Leventhal AM; David SP; Brightman M; Strong D; McGeary JE; Brown RA; Lloyd-Richardson EE; Munafò M; Uhl GR; Niaura R
    Pharmacogenomics J; 2012 Feb; 12(1):86-92. PubMed ID: 20661272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.
    David SP; Brown RA; Papandonatos GD; Kahler CW; Lloyd-Richardson EE; Munafò MR; Shields PG; Lerman C; Strong D; McCaffery J; Niaura R
    Nicotine Tob Res; 2007 Aug; 9(8):821-33. PubMed ID: 17654295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.
    David SP; Strong DR; Leventhal AM; Lancaster MA; McGeary JE; Munafò MR; Bergen AW; Swan GE; Benowitz NL; Tyndale RF; Conti DV; Brown RA; Lerman C; Niaura R
    Addiction; 2013 Dec; 108(12):2202-11. PubMed ID: 23941313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence.
    Bergen AW; Javitz HS; Su L; He Y; Conti DV; Benowitz NL; Tyndale RF; Lerman C; Swan GE
    Nicotine Tob Res; 2013 Jul; 15(7):1190-200. PubMed ID: 23212438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.
    Cox LS; Nollen NL; Mayo MS; Choi WS; Faseru B; Benowitz NL; Tyndale RF; Okuyemi KS; Ahluwalia JS
    J Natl Cancer Inst; 2012 Feb; 104(4):290-8. PubMed ID: 22282543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in food reward following smoking cessation: a pharmacogenetic investigation.
    Lerman C; Berrettini W; Pinto A; Patterson F; Crystal-Mansour S; Wileyto EP; Restine SL; Leonard DG; Shields PG; Epstein LH
    Psychopharmacology (Berl); 2004 Aug; 174(4):571-7. PubMed ID: 15138759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
    Aubin HJ; Lebargy F; Berlin I; Bidaut-Mazel C; Chemali-Hudry J; Lagrue G
    Addiction; 2004 Sep; 99(9):1206-18. PubMed ID: 15317642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.
    Faseru B; Nollen NL; Mayo MS; Krebill R; Choi WS; Benowitz NL; Tyndale RF; Okuyemi KS; Ahluwalia JS; Sanderson Cox L
    Addict Behav; 2013 Mar; 38(3):1796-803. PubMed ID: 23254230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.
    Tonstad S; Farsang C; Klaene G; Lewis K; Manolis A; Perruchoud AP; Silagy C; van Spiegel PI; Astbury C; Hider A; Sweet R
    Eur Heart J; 2003 May; 24(10):946-55. PubMed ID: 12714026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials.
    David SP; Strong DR; Munafò MR; Brown RA; Lloyd-Richardson EE; Wileyto PE; Evins AE; Shields PG; Lerman C; Niaura R
    Nicotine Tob Res; 2007 Dec; 9(12):1251-7. PubMed ID: 18058343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.
    Ahluwalia JS; Harris KJ; Catley D; Okuyemi KS; Mayo MS
    JAMA; 2002 Jul 24-31; 288(4):468-74. PubMed ID: 12132977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).
    Chen LS; Bloom AJ; Baker TB; Smith SS; Piper ME; Martinez M; Saccone N; Hatsukami D; Goate A; Bierut L
    Addiction; 2014 Jan; 109(1):128-137. PubMed ID: 24033696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.
    Tønnesen P; Tonstad S; Hjalmarson A; Lebargy F; Van Spiegel PI; Hider A; Sweet R; Townsend J
    J Intern Med; 2003 Aug; 254(2):184-92. PubMed ID: 12859700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees.
    Dalsgareth OJ; Hansen NC; Søes-Petersen U; Evald T; Høegholm A; Barber J; Vestbo J
    Nicotine Tob Res; 2004 Feb; 6(1):55-61. PubMed ID: 14982688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation.
    Quaak M; van Schayck CP; Postma DS; Wagena EJ; van Schooten FJ
    Addiction; 2012 Jan; 107(1):178-87. PubMed ID: 21658141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch.
    David SP; Munafò MR; Murphy MF; Proctor M; Walton RT; Johnstone EC
    Pharmacogenomics J; 2008 Apr; 8(2):122-8. PubMed ID: 17387332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
    Lee AM; Jepson C; Hoffmann E; Epstein L; Hawk LW; Lerman C; Tyndale RF
    Biol Psychiatry; 2007 Sep; 62(6):635-41. PubMed ID: 17223085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of bupropion in the indigenous Maori population in New Zealand.
    Holt S; Timu-Parata C; Ryder-Lewis S; Weatherall M; Beasley R
    Thorax; 2005 Feb; 60(2):120-3. PubMed ID: 15681499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.